Calcium channel blocker compared with angiotensin receptor blocker for patients with hypertension: a meta-analysis of randomized controlled trials

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Hypertension management involves various drug classes.
• Calcium channel blockers (CCBs) and angiotensin II receptor blockers (ARBs) are commonly prescribed antihypertensives.
• Comparative effectiveness data is crucial for optimal treatment selection.

Purpose of the Study:

• To compare the clinical efficacy of CCBs versus ARBs in hypertensive patients.
• To evaluate the impact on all-cause mortality, stroke, myocardial infarction, and heart failure.

Main Methods:

• Meta-analysis of eight head-to-head randomized controlled trials.
• Inclusion of 25,084 patients with hypertension.
• Pooled analysis of key cardiovascular outcomes.

Main Results:

• No significant difference in all-cause mortality between CCBs and ARBs (RR, 0.99; 95% CI, 0.91-1.07).
• CCBs demonstrated superior efficacy in reducing stroke (RR, 0.87; 95% CI, 0.76-0.99) and myocardial infarction (RR, 0.86; 95% CI, 0.76-0.98) incidence.
• No significant difference in heart failure incidence, with a trend towards lower incidence with ARBs (RR, 1.4; 95% CI, 0.99-1.98).

Conclusions:

• Initial use of CCBs may offer advantages over ARBs for preventing stroke and myocardial infarction in hypertensive individuals.
• Further research may clarify the role of ARBs in heart failure prevention.